Literature DB >> 7946270

Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.

O Ciofu1, B Giwercman, S S Pedersen, N Høiby.   

Abstract

At the Danish CF Center patients with chronic Pseudomonas aeruginosa lung infection were treated 3-4 times a year (from 1976) with a 2-week intravenous antipseudomonal course which included preferentially an aminoglycoside and a beta-lactam antibiotic. We investigated the development of antibiotic resistance in P. aeruginosa strains isolated from Danish CF patients over a period of 18 years by testing the in vitro efficacy of carbenicillin, piperacillin, ceftazidime, tobramycin and ciprofloxacin against P. aeruginosa strains collected in 1973 (51 strains), 1980 (80 strains), 1985 (58 strains), and 1991 (100 strains). All the strains were screened and assayed semiquantitatively for beta-lactamase activity by use of nitrocefin. We found a significant (p < 0.005) increase in the MIC values of the P. aeruginosa strains against piperacillin and ceftazidime. However, no significant correlation was found between the MIC and the number of antipseudomonal courses of antibiotics. The proportion of resistant in vivo selected P. aeruginosa strains, presumed to be stably derepressed producers of chromosomal beta-lactamase, also increased significantly during the period studied. Our results confirm that the beta-lactamase production is an important mechanism of antibiotic resistance in P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946270

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  24 in total

1.  Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.

Authors:  Christiane Beckmann; Mitchell Brittnacher; Robert Ernst; Nicole Mayer-Hamblett; Samuel I Miller; Jane L Burns
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 2.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

3.  Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.

Authors:  Kim Thomsen; Lars Christophersen; Peter Østrup Jensen; Thomas Bjarnsholt; Claus Moser; Niels Høiby
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  R M Shawar; D L MacLeod; R L Garber; J L Burns; J R Stapp; C R Clausen; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients.

Authors:  Samuel M Moskowitz; Mark K Brannon; Nandini Dasgupta; Miyuki Pier; Nicole Sgambati; Amanda K Miller; Sara E Selgrade; Samuel I Miller; Miles Denton; Steven P Conway; Helle K Johansen; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

6.  Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.

Authors:  T D Petersen; O Ciofu; T Pressler; B Giwercman; S S Pedersen; N Høiby
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

7.  Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD.

Authors:  Niels Bagge; Oana Ciofu; Morten Hentzer; Joan I A Campbell; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

Authors:  T L Pitt; M Sparrow; M Warner; M Stefanidou
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

9.  Computational discovery of putative quorum sensing inhibitors against LasR and RhlR receptor proteins of Pseudomonas aeruginosa.

Authors:  Angusamy Annapoorani; Venugopal Umamageswaran; Radhakrishnan Parameswari; Shunmugiah Karutha Pandian; Arumugam Veera Ravi
Journal:  J Comput Aided Mol Des       Date:  2012-09-18       Impact factor: 3.686

10.  The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa.

Authors:  Alfredo Castañeda-García; Alexandro Rodríguez-Rojas; Javier R Guelfo; Jesús Blázquez
Journal:  J Bacteriol       Date:  2009-09-04       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.